Access to immunotherapy in the second line (PD-1 inhibitors with or without a CTLA-4 inhibitor) is restricted to certain countries and, while not supported by survival benefit, should be discussed on a case-by-case basis, in light of the evidence of disease-modulating activity in advanced HCC. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.